Twelve-week, prospective, open-label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add-on therapy to an alpha-blocker for lower urinary tract symptoms

Clinical Interventions in Aging

Volumn 9, Issue , 2014, Pages 1021-1030

  Shin, Yu Seob ^a   Zhang, Li Tao ^a   Zhao, Chen ^b   Kim, Young Gon ^a   Park, Jong Kwan ^a  

^a Chonbuk National University Medical School   (South Korea)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Benign prostatic hyperplasia; Luts; Nocturia; Nocturnal bladder capacity

Indexed keywords

DESMOPRESSIN; SOLIFENACIN; TAMSULOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDIURETIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ADD ON THERAPY; AGED; ARTICLE; BEDTIME DOSAGE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; NOCTURIA; OPEN STUDY; POLYURIA; POSTVOID RESIDUAL URINE VOLUME; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; UROFLOWMETRY; BLADDER; DRUG COMBINATION; DRUG EFFECTS; LOWER URINARY TRACT SYMPTOMS; MIDDLE AGED; PROSTATIC HYPERPLASIA; URINARY BLADDER, OVERACTIVE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; ANTIDIURETIC AGENTS; CHOLINERGIC ANTAGONISTS; DRUG THERAPY, COMBINATION; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; NOCTURIA; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER, OVERACTIVE;

EID: 84904303735     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S64194     Document Type: Article

References (21)

1. Blake-James BT, Rashidian A, Ikeda Y, Emberton M. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int. 2007;99(1):85-96.
2. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49(4):651-658.
3. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006; 50(6):1306-1314.
4. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003;169(6):2253-2256.
5. Lee KS, Choo MS, Kim DY, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol. 2005;174(4 Pt 1): 1334-1338.
6. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296(19):2319-2328.
7. Ali A, Snape J. Nocturia in older people: a review of causes, consequences, assessment and management. Int J Clin Pract. 2004;58(4): 366-373.
8. Yoshimura K, Ohara H, Ichioka K, et al. Nocturia and benign prostatic hyperplasia. Urology. 2003;61(4):786-790.
9. Chang SC, Lin AT, Chen KK, Chang LS. Multifactorial nature of male nocturia. Urology. 2006;67(3):541-544.
10. Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int. 2002;89(9):855-862.
11. Lose G, Mattiasson A, Walter S, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol. 2004;172(3): 1021-1025.
12. Weiss JP, Zinner NR, Klein BM, Nørgaard JP. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. Neurourol Urodyn. 2012;31(4): 441-447.
13. Kirby RS. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int. 2003;91:41-44.
14. Homma Y, Yoshida M, Seki N, Yokoyama O, et al. Symptom assessment tool for overactive bladder syndrome - overactive bladder symptom score. Urology. 2006;68:318-323.
15. Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol. 2001;166(2):550-552.
16. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int. 2004;94(6): 817-820.
17. Lee SH, Chung BH, Kim SJ, Kim JH, Kim JC, Lee JY. Initial combined treatment with anticholinergics and a-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer Prostatic Dis. 2011;14(4):320-325.
18. Asplund R, Aberg H. Diurnal variation in the levels of antidiuretic hormone in the elderly. J Intern Med. 1991;229(2):131-134.
19. Abrams P, Klevmark B. Frequency volume charts: an indispensable part of lower urinary tract assessment. Scand J Urol Nephrol Suppl. 1996;179:47-53.
20. Matthiesen TB, Rittig S, Mortensen JT, Djurhuus JC. Nocturia and polyuria in men referred with lower urinary tract symptoms, assessed using a 7-day frequency-volume chart. BJU Int. 1999;83(9):1017-1022.
21. Tincello DG, Williams KS, Joshi M, Assassa RP, Abrams KR. Urinary diaries: a comparison of data collected for three days versus seven days. Obstet Gynecol. 2007;109(2 Pt 1):277-280.